Trials / Completed
CompletedNCT06738433
Efficacy and Tolerability of ABB I5 Prebiotic and ABB C22 Postbiotics for the Management of Constipation and Gastrointestinal Well-being: a Pilot Trial
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- AB Biotek · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study, we aim at assessing the benefits of dietary supplementation with ABB i5 and ABB C24, a combination of the the prebiotic ABB i5 and the postbiotic ABB C22, on the gut microbiota of people with constipation and on their gastrointestinal well-being.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | ABB i5 | Prebiotic ABB i5 (NextDext®, 5g) |
| DIETARY_SUPPLEMENT | ABB C24 | ABB C24: Prebiotic ABB i5 (NextDext®, 5g) + yeast postbiotic ABB C22 (200 mg) in sachets containing 5,2 g |
Timeline
- Start date
- 2023-04-25
- Primary completion
- 2024-04-04
- Completion
- 2024-04-04
- First posted
- 2024-12-17
- Last updated
- 2024-12-17
Locations
1 site across 1 country: South Sudan
Source: ClinicalTrials.gov record NCT06738433. Inclusion in this directory is not an endorsement.